Eczema is a skin-barrier and immune condition that flares and settles, and it starts in the skin, not the diet. The care that holds it down is plain and reliable: moisturize a lot, and treat flares promptly with a topical steroid. Fear of that cream does more harm than the cream does, because people who are afraid of it use too little and their eczema quietly stays active. Calcineurin creams suit the face and other delicate skin, and dabbing an anti-inflammatory cream on the usual trouble spots twice a week keeps the next flare off.
For eczema that covers much of the body and will not settle, dupilumab and the JAK-inhibitor tablets are effective. Two popular ideas did not survive their trials: food-elimination diets do little for most eczema and can bring on a new food allergy, and daily baby moisturizer did not prevent eczema in the infants most likely to get it. There is one emergency, eczema herpeticum, and it is at the end.
This page covers:
- what works
- what does not
- the Chinese medicine reading by pattern
- the few signs that need care the same day
Practice Ranking
Every practice we track for Eczema, ranked by how well the evidence supports it for this condition. Strength describes the evidence, not our endorsement.
2 practices · 0 to start with
| # | Practice | Evidence | Type | Cost | Effort | Results In | Add to plan |
|---|---|---|---|---|---|---|---|
| 1 | Vitamin D Vitamin D helps eczema mainly in people who are deficient, a cheap add-on rather than a standalone fix. | Emerging | Supplement | $ | Easy | Weeks to Months | |
| 2 | Probiotics For eczema you already have, probiotics made little or no difference, so they are not worth relying on. | Moderate | Supplement | $ to $$ | Easy | Days to Weeks | |
Default order puts the best-supported practices first, with self-directed care ahead of clinical options. Click any row to open the practice.
What It Is
Eczema, or atopic dermatitis, is a condition of the skin barrier and the immune system, and it is not a food allergy. It is common, affecting around one in five children and about one in twenty adults, and it runs in flares and calmer spells. Where it comes from points to the treatment that works.
The outer layer of skin is meant to hold water in and keep irritants, allergens and microbes out. In eczema that barrier is leaky. A common inherited weakness in a skin protein called filaggrin is the strongest known risk factor: it lets moisture escape and lets irritants and allergens through. The immune system then overreacts to what gets in, and that inflammation weakens the barrier further, so each worsens the other. This is why the skin is dry, why it flares, and why treating the skin is the foundation of care.
The itch is the worst of it, and it feeds a cycle. Scratching relieves it for a moment and damages the barrier a little more, which lets in more of what inflames the skin, which itches more. The trigger for a flare differs from person to person:
- heat and sweat
- harsh soaps
- low humidity
- wool worn straight against the skin
- stress
Flares tend to settle into the creases of the elbows and knees, the wrists, the ankles, the neck, and in babies the cheeks and scalp.
Eczema often comes first in a sequence called the atopic march, which can go on to include food allergy, asthma and hay fever, because the same barrier-and-immune tendency underlies all of them. Having eczema does not mean the rest will follow, but it explains why they often occur together, and why repairing the skin barrier has effects beyond the skin itself.
What Helps
The care that works for eczema is mostly done at home, day after day. Two things do the most and are the most underrated: moisturizing a lot, and using the anti-inflammatory cream properly when the skin flares. The two home mainstays come first, then the clinic-based options for severe disease.
Moisturizing does the most of anything you do at home. Applied generously and often, all over and every day, plain emollients roughly halved flares in the trials, pushed the next flare from about a month away to about six months away, and cut how much steroid cream people needed. The amount matters more than the brand. Keep it up even when the skin looks clear, because that is what holds the next flare off.
Topical steroid creams are the main treatment that settles a flare, and used correctly they are safe. In the trials about two in three people improved on the steroid against about one in three on the moisturizer base, and side effects were no more common than in the moisturizer group. Use them in short courses on active eczema, at a potency matched to the site: mild on the face, stronger on thick skin. The thinning people worry about comes from prolonged strong steroids on delicate areas, not from treating flares as directed, and getting the strength right is covered in the cautions.
The belief that these creams are dangerous is a large part of why eczema stays bad. Fear of steroids is common, and in the studies that measured it, people who feared the cream skipped treatment far more often, with nonadherence around 49% against 14%.
The fear of the cream does more harm through undertreatment than correct use of the cream does.
Tacrolimus and pimecrolimus, the topical calcineurin inhibitors, control eczema without steroids, and in the large network of trials they improved five to six of seven eczema outcomes without increasing harm. They do not thin the skin, so they are the first choice for the face, the eyelids and the skin folds, where prolonged steroids are riskiest. A short-lived stinging when first applied usually settles within a week.
Once the skin is calm, twice-weekly maintenance keeps it calm. Dabbing an anti-inflammatory cream on the usual trouble spots twice a week pushed the median time to the next flare from 15 days to 142 days in the trial that tested it. Keep treating the skin that keeps flaring even after it looks normal; this prevents the next flare instead of waiting to react to one.
Two bathing measures help at the more troublesome end. For eczema that keeps getting infected, dilute bleach baths calmed clinician-rated severity by around 22%: about half a cup of standard bleach in a full tub two or three times a week, followed by rinsing and moisturizing. Plain lukewarm water baths did nearly as well, so much of the benefit is the bathing-and-moisturizing routine itself, and the plain version is fine if the bleach is off-putting.
For a severe flare, wet wraps, damp bandages over emollient and steroid, can settle the skin quickly as a short-term measure. The formal evidence that they beat ordinary steroid treatment is thin, and they can slightly raise the chance of a mild skin infection, so they are used for a few days rather than as routine care.
For eczema that covers much of the body and does not respond to creams, there are effective specialist options. Dupilumab, an injected biologic that blocks the type-2 inflammation central to eczema, cleared or nearly cleared the skin in about a third of people against under one in ten on placebo, and calmed the itch alongside it.
The oral JAK inhibitors, such as abrocitinib and upadacitinib, work fast and strongly. In a head-to-head trial abrocitinib eased itch faster than dupilumab, 48% against 26% reaching a meaningful itch improvement by two weeks. They need blood-test monitoring and carry class safety warnings, so they belong in a dermatology clinic.
Phototherapy sits between the creams and these systemic drugs. A course of narrowband UVB light at a clinic eased eczema and itch in the trials, on low-certainty evidence, and it means regular visits instead of a tablet or an injection.
Two lower-key options round out the ladder. A vitamin D supplement is a cheap, low-risk add-on that modestly improved severity in the pooled trials, most worth trying if you run low or through darker months. Chinese herbal medicine showed a modest edge on recovery rates in the trials, covered in its own section below. Both sit well behind the mainstays, as extras. The full research, graded at its own strength, is here.
The Research & Studies
Everything here is based on the research we have collected and checked, sorted into groups and ordered with the strongest evidence first. Click any claim to open the studies behind it.
Skin And Hair
Topical steroids settled eczema flares in 65% of people versus 32% on the base cream
Steroid creams are the main treatment that settles an eczema flare. In the trials about two in three people improved on the steroid against about one in three on the moisturizer base, and side effects were no more common than in the moisturizer group.
This meta-analysis pooled 12 RCTs (2224 participants) of topical corticosteroid against vehicle or moisturizer in childhood eczema. Responders were 0.65 (95% CI 0.54 to 0.74) on steroid versus 0.32 (0.20 to 0.48) on vehicle, with similar adverse events (0.17 vs 0.12). Mild, reversible adrenal suppression was recorded in 4 of 157 tested children (3%). Ten of the twelve trials were industry-sponsored and heterogeneity was high, so the effect size is approximate; the direction of benefit is not in doubt and is consistent across the wider guideline evidence.
Used in short courses on active eczema, at a potency matched to the site (mild on the face, stronger on thick or lichenified skin), these are safe and effective. The skin thinning people fear comes from long unbroken use of strong steroids on delicate areas, not from treating flares as directed.
The study · 1
Fishbein et al., systematic review of topical corticosteroids in paediatric atopic dermatitis · J Pediatr Nurs 2019;47:36-43
Calcineurin creams improved five to six of seven eczema outcomes without thinning skin
Tacrolimus and pimecrolimus ointments are a steroid-free way to control eczema, and they worked as well as mid-strength steroid creams across most outcomes. Because they do not thin skin, they suit the face, eyelids and skin folds.
The 2023 AAAAI/ACAAI network meta-analysis evaluated 68 interventions across 219 trials. Pimecrolimus improved six of seven outcomes (among the best for two), tacrolimus 0.1% improved five (among the best for two), and both, alongside mid-potency steroids, were among the most effective for maintaining control, all with high-certainty evidence and no increase in harm. Their advantage over steroids is anatomical: they do not cause skin atrophy, so they are used where prolonged steroids are risky. A transient burning or stinging on application is the common early complaint.
These are the first choice for eczema on thin skin, the face, eyelids and folds, where they avoid the thinning that strong steroids can cause. A short-lived stinging when first applied usually settles within a week.
The study · 1
Chu et al., Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials · J Allergy Clin Immunol 2023;152(6):1493-1519
Dupilumab cleared or nearly cleared the skin in 36 to 38% versus 8 to 10% on placebo
For eczema that covers much of the body and does not respond to creams, the injected biologic dupilumab clears or nearly clears the skin in about a third of people, against under one in ten on placebo, and it calms the itch alongside it.
SOLO 1 (671 patients) and SOLO 2 (708 patients) randomized adults with moderate-to-severe atopic dermatitis to weekly or fortnightly dupilumab 300 mg or placebo for 16 weeks. The co-primary clear/almost-clear outcome was reached by 36-38% on dupilumab versus 8-10% on placebo, with significantly more achieving a 75% improvement in the Eczema Area and Severity Index, and improvements in pruritus, anxiety, depression and quality of life. Dupilumab blocks interleukin-4 and interleukin-13 signaling, the type-2 inflammation central to eczema. Injection-site reactions and conjunctivitis were more common than with placebo.
This is a specialist-prescribed option for eczema that is extensive or unresponsive to topical treatment, not a first step; it is given by injection and continued long term while it works.
The study · 1
Simpson et al., Two phase 3 trials of dupilumab versus placebo in atopic dermatitis · N Engl J Med 2016;375(24):2335-2348
Oral JAK inhibitors eased itch faster than dupilumab, 48% versus 26% at two weeks
The newer oral JAK-inhibitor tablets, such as abrocitinib and upadacitinib, work fast and strongly on severe eczema, easing itch within a couple of weeks and, in a direct comparison, clearing skin faster than the injected biologic. They need blood-test monitoring and specialist supervision.
This double-blind phase 3 trial randomized 727 adults to oral abrocitinib 200 mg daily or subcutaneous dupilumab 300 mg fortnightly for 26 weeks, both on background topical therapy. Abrocitinib produced greater early itch response (PP-NRS4 at week 2: 48% versus 26%, difference 22.6%) and greater EASI-90 at week 4 (29% versus 15%). JAK inhibitors block cytokine signaling broadly, which brings speed but also a class safety profile, boxed warnings covering serious infections, blood clots, cardiovascular events and malignancy drawn largely from an older rheumatoid-arthritis population, that requires baseline and periodic blood monitoring.
A specialist option for severe eczema when fast relief matters or biologics have not been enough; it is a daily tablet with required blood monitoring, so it belongs in a dermatology clinic rather than a self-directed plan.
The study · 1
Reich et al., abrocitinib versus dupilumab in atopic dermatitis (JADE DARE) · Lancet 2022;400(10348):273-282
Daily moisturizer roughly halved eczema flares and stretched time-to-flare from 30 to 180 days
Using a moisturizer every day, all over, is the foundation of eczema care. In the trials it roughly halved flares, pushed the next flare from about a month away to about six months away, and cut how much steroid cream people needed.
The Cochrane review pooled 77 randomized trials (6603 participants). Moisturizer versus no moisturizer lowered the SCORAD severity score modestly (3 studies, mean difference -2.42), a change below the pre-set important threshold, but the flare and steroid-sparing outcomes were the practically meaningful ones: fewer flares (RR 0.40), median time to flare 180 versus 30 days, and 9.3 g less topical corticosteroid used. Adding an active anti-inflammatory to a moisturizer worked better than the moisturizer alone. Most included studies were rated at high or unclear risk of bias and the certainty was low, which is why this sits at moderate rather than strong.
The amount matters more than the brand: apply a plain emollient generously and often, and keep it up when the skin looks clear, because that is what holds the next flare off.
The study · 1
van Zuuren et al., Emollients and moisturisers for eczema (Cochrane review) · Cochrane Database Syst Rev 2017;2:CD012119
Fear of steroid creams pushed nonadherence to 49% versus 14%, leaving eczema undertreated
Fear of steroid creams is very common, and it is a major driver of eczema staying bad: people who fear the cream use far less of it, so their eczema does not settle. The cream itself is not the problem here; not using it is.
The review synthesized 16 cross-sectional studies. Reported prevalence of steroid phobia ranged widely (21.0% to 83.7%) partly because studies defined it differently, from reasonable caution to irrational fear. Where adherence was measured, the phobia groups had roughly three to four times the nonadherence. The information driving the fear came from clinicians, family, media and the internet. This is a claim about beliefs and behavior rather than a treatment effect, so it carries no direction.
The study · 1
Li et al., Topical corticosteroid phobia in atopic dermatitis: a systematic review · JAMA Dermatol 2017;153(10):1036-1042
Twice-weekly maintenance pushed the next flare from 15 to 142 days away
Once eczema is calm, dabbing the anti-inflammatory cream on the usual trouble spots twice a week keeps it calm. In the trial this pushed the next flare from about two weeks away to nearly five months away.
After an open-label settling phase, 224 adults in remission were randomized to twice-weekly tacrolimus 0.1% (n=116) or vehicle (n=108) for 12 months, treating flares openly when they occurred. Proactive treatment reduced the number of disease exacerbations needing substantial intervention (median difference 2, p<0.001), lowered the proportion of treatment days, and extended median time to first flare to 142 versus 15 days. Adverse events were similar between arms. The same proactive principle is applied with intermittent topical steroids and is a standard guideline strategy for recurrent eczema.
The move is to keep treating the skin that keeps flaring even after it looks normal: two applications a week to those spots, rather than waiting for the next flare and starting over.
The study · 1
Wollenberg et al., Proactive treatment of atopic dermatitis in adults with 0.1% tacrolimus ointment · Allergy 2008;63(7):742-750
Dilute bleach baths cut clinician-rated eczema severity by about 22%, and water baths did nearly as well
A twice-weekly bath with a small amount of household bleach, about half a cup in a full tub, modestly calms moderate-to-severe eczema, mostly the visible severity a clinician scores. Whether it helps itch or sleep is not clear, and plain water baths did nearly as well.
The Bayesian meta-analysis pooled 10 RCTs (307 participants, median trial duration 6 weeks) of bleach versus no-bleach baths. Bleach baths probably improved the Eczema Area and Severity Index by a relative 22% (ratio of means 0.78, moderate certainty) and may slightly reduce Staphylococcus aureus colonization (RR 0.89, low certainty). Patient-reported severity, itch, sleep, quality of life and flare risk did not clearly differ, at low to very low certainty. Here the comparator was water baths, which were nearly as effective, so much of the benefit may be the bathing-and-moisturizing routine itself rather than the bleach.
Worth trying for moderate-to-severe eczema that keeps getting infected, at roughly half a cup of standard bleach in a full bath, two or three times a week, followed by rinsing and moisturizing. Plain lukewarm baths followed by moisturizer capture most of the same benefit if the bleach is off-putting.
The study · 1
Bakaa et al., Bleach baths for atopic dermatitis: a systematic review and meta-analysis including unpublished data, Bayesian interpretation, and GRADE · Ann Allergy Asthma Immunol 2022;128(6):660-668.e9
Food-elimination diets gave at most a slight 9% gain and can trigger new food allergy
Cutting foods out of the diet does little for eczema, and it can backfire. Across the trials the improvement was small and may not be noticeable, and dropping a food such as egg or milk can lead to a food allergy to it later.
The systematic review pooled 10 RCTs (599 participants; median study mean age 1.5 years, median SCORAD 20.7). Compared with no elimination, dietary elimination gave a low-certainty, slight improvement in eczema severity (risk difference 9%, CI 0 to 17), pruritus and sleeplessness, with no credible difference between empiric elimination and testing-guided elimination or by sensitization status. Harms were poorly reported within the trials, but indirect evidence indicates that removing a food from a child who was tolerating it can lead to loss of tolerance and IgE-mediated allergy on reintroduction. Eczema is a skin-barrier and immune condition; food allergy is a common coexisting problem but is rarely the driver of the eczema itself, so broad elimination trades a small possible gain for nutritional and allergy risk. This finding is two-sided, so it carries no single direction.
Rather than cutting out foods, treat the skin: emollients and anti-inflammatory creams do far more. Keep a food on board unless a clear, immediate reaction or a clinician's assessment points to it, because removing a tolerated food is what creates the allergy people fear.
The study · 1
Oykhman et al., Dietary elimination for the treatment of atopic dermatitis: a systematic review and meta-analysis · J Allergy Clin Immunol Pract 2022;10(10):2657-2666.e8
Daily baby moisturizer did not prevent eczema in at-risk infants, 31% versus 28%
Moisturizing a baby from birth was hoped to head off eczema before it starts. In the large trial that tested it, it did not: eczema was just as common in the babies who were moisturized daily. Moisturizers treat eczema well, but they do not prevent it.
BEEP randomized 1394 high-risk term infants to daily emollient plus standard advice or standard advice alone for the first year, with follow-up to age 5. Clinical eczema between 12 and 60 months occurred in 31% of the emollient group versus 28% of controls (adjusted RR 1.10), and food allergy, asthma and hay fever were similar between groups. This mirrors the wider Cochrane conclusion that skin-care interventions in infancy do not prevent eczema and may modestly increase skin infections. It is a clean example of a plausible prevention idea not surviving a large trial, and it shows that emollients work as treatment, not as prophylaxis.
The study · 1
Bradshaw et al., Emollients for prevention of atopic dermatitis: 5-year findings from the BEEP randomized trial · Allergy 2023;78(4):995-1006
Probiotics made little or no difference to eczema you already have, across 39 trials
Probiotic supplements do not clear eczema you already have. Pooling 39 trials, they made little or no difference to how itchy or bad the eczema was, or to quality of life.
The 2018 Cochrane review included 39 RCTs (2599 participants, first year of life to 55 years, only six studies in adults) of probiotics versus no probiotics, placebo or other treatment for treating eczema. Probiotics showed little or no difference in participant- or parent-rated eczema symptoms at the end of treatment, and no meaningful change in quality of life, with the evidence graded low to moderate certainty. Trial sequential analysis supported that the symptom result was unlikely to change with more of the same trials. This is a distinct question from prevention in high-risk infants, where the evidence is separate and more mixed.
The study · 1
Makrgeorgou et al., Probiotics for treating eczema (Cochrane review) · Cochrane Database Syst Rev 2018;11:CD006135
Wet wraps can calm a severe flare quickly, on low-quality evidence from six small trials
Wrapping steroid-treated skin in a damp then dry layer can calm a severe flare fast, and it is a recognized hospital and short-course technique. The formal evidence that it beats ordinary steroid treatment is thin, and it can slightly raise the chance of a mild skin infection.
The review located only six RCTs, each small (19 to 51 patients), comparing wet-wrap therapy with conventional topical treatment. Severity and quality-of-life reporting was incomplete and heterogeneous, and overall certainty was low, so a clear advantage over topical steroids alone could not be established. A non-significant trend toward mild skin infection was seen (RR 6.35, wide CI 0.83 to 48.55). In practice wet wraps are used as a short-term intensive measure for severe or refractory flares, often under specialist guidance, rather than as routine daily care.
This is a short-term rescue technique for a severe flare, not everyday care: applied for a few days over emollient and steroid, ideally with guidance the first time, and stopped once the skin settles.
The study · 1
Gonzalez-Lopez et al., Efficacy and safety of wet wrap therapy for patients with atopic dermatitis: a systematic review and meta-analysis · Br J Dermatol 2017;177(3):688-695
Narrowband UVB light treatment eased eczema and itch, on low-certainty evidence
For eczema that covers a lot of skin and is not settling with creams, a course of narrowband UVB light at a dermatology clinic calmed the eczema and eased the itch in the trials. It sits between the creams and the strong systemic drugs, and it means regular trips to the clinic.
The 2021 Cochrane review pooled 32 RCTs (1219 participants, aged 5 to 83, mean 28, recruited mostly from dermatology clinics, average 13 weeks of treatment). Narrowband UVB was the most-studied of the light treatments (13 trials). Against placebo or no treatment it improved physician-assessed signs (mean difference -9.4 on a 0 to 90 scale; 1 trial, 41 participants), the number of people reporting reduced itch (risk ratio 1.72; 1 trial, 40 participants), and global improvement (risk ratio 2.81, 95% CI 1.10 to 7.17; 1 trial, 41 participants), with no difference in withdrawals for side effects. Each of these key comparisons rested on a single small trial and the certainty was low. Comparisons of narrowband UVB against UVA1 and PUVA were very low certainty. Phototherapy is a guideline-recognized second-line option, delivered as repeated short sessions over weeks, used when topical treatment is not enough and before or instead of systemic drugs.
Who this may not transfer to:Participants were mostly secondary-care dermatology patients with more troublesome eczema, so this reflects second-line clinic use rather than mild eczema managed at home; the key narrowband UVB findings each rest on a single small trial.
This is a clinic-based option for widespread eczema that topicals have not controlled, given as repeated short light sessions over several weeks. It avoids systemic medicines but needs regular visits, and the total ultraviolet dose over the years is kept in mind because cumulative UV ages the skin and adds to skin-cancer risk.
The study · 1
Musters et al., Phototherapy for atopic eczema (Cochrane review) · Cochrane Database Syst Rev 2021;10(10):CD013870
Chinese herbal medicine modestly raised recovery rates but did not move standardized severity scores
Chinese herbal formulas showed a modest edge in the pooled trials, more people rated as recovered and fewer relapses, but the harder severity measures did not clearly move, and most trials were small and of limited quality. It is a promising signal rather than settled evidence.
The 2023 meta-analysis pooled 17 RCTs (1624 patients). Chinese herbal medicine raised the overall recovery rate (RR 1.15) and reduced recurrence (OR 0.19), both robust to sensitivity analysis, with adverse-event rates no different from controls. But the objective severity scales told a weaker story: no significant difference on EASI or quality of life, and the SCORAD improvement did not survive sensitivity analysis. Most trials were small and conducted in single regions, which is why this sits at emerging. Earlier Cochrane reviews reached a more cautious conclusion of insufficient evidence. A separate, serious concern is that some marketed herbal eczema products have been found adulterated with undeclared corticosteroids, so the safety of an unverified product is not the safety of the studied formula.
Who this may not transfer to:The trials were almost all conducted in China and did not report results by sex; how far the formulas and findings transfer to other populations and to each sex is not established.
If you want to explore herbal treatment, do it through a qualified practitioner using a traceable supply, not an unlabeled cream bought online, because adulteration with hidden steroids is a documented problem in this market.
The study · 1
Jia et al., An updated systematic review and meta-analysis of efficacy and safety of Chinese herbal medicine for treating atopic dermatitis · J Dermatolog Treat 2023;34(1):2268766
Vitamin D supplementation modestly improved eczema severity, most in people who run low
People with eczema tend to run lower on vitamin D, more so when the eczema is bad, and taking vitamin D modestly improved severity in the trials. It is a low-risk add-on worth considering, especially if you are deficient, not a substitute for skin treatment.
The meta-analysis of 20 studies (1882 AD cases) found significantly lower serum 25(OH)D in people with eczema than controls, lower still in severe versus mild-to-moderate disease, and a significant improvement in severity with supplementation. The authors caution that season, sunlight exposure and cultural practices confound the vitamin-D-and-eczema relationship, and that the randomized evidence on supplementation is still limited, which keeps this at emerging. The plausible mechanism is vitamin D's role in the skin barrier and antimicrobial peptide production, but causal direction is not settled.
A daily vitamin D supplement is cheap, safe at standard doses and reasonable to try as an adjunct, particularly through darker months or if a blood test shows you are low; treat the skin as the main task and view this as a possible extra.
The study · 1
Ng and Yew, vitamin D and atopic dermatitis: systematic review and meta-analysis · Am J Clin Dermatol 2022;23(3):267-275
How it works
Eczema begins in a faulty skin barrier and a type-2 immune overreaction, not the diet
Eczema starts in the skin barrier, not the diet. A common genetic fault in a skin protein called filaggrin lets moisture out and irritants in, and the immune system then overreacts, which is why relentless moisturizing and calming the inflammation are the two things that work.
Atopic dermatitis affects around 20% of children and 5% of adults. The outermost skin layer, the stratum corneum, normally keeps water in and allergens and microbes out. Loss-of-function FLG mutations are the key inherited risk factor, weakening that barrier; type-2 inflammatory cytokines (including interleukin-4 and interleukin-13) then suppress other barrier genes, change the lipid composition, and drive the itch-scratch cycle. The barrier defect lets in allergens and lets Staphylococcus overgrow, feeding the inflammation. This mechanism is why the treatments that work target the barrier (emollients) and the type-2 inflammation (steroids, calcineurin inhibitors, dupilumab), and why treating the skin, rather than hunting a food, is the foundation.
The study · 1
Stefanovic and Irvine, the role of the skin barrier in atopic dermatitis · Ann Allergy Asthma Immunol 2024;132(2):187-195
What Does Not Help
A few widely tried approaches do little for eczema, and one carries a risk of its own. Skipping them saves money, effort, and in one case a harm.
Broad food-elimination diets are the big one. Cutting foods out does little for most eczema, and it can backfire. Across the trials the improvement was slight and may not be noticeable, at most about a 9% gain, and guiding the elimination by allergy tests gave no advantage.
The main harm is to children. Dropping a food a child was tolerating, such as egg or milk, can lead to an immediate food allergy to it later. Eczema is a skin-barrier and immune condition; food allergy travels with it but rarely drives it, so broad elimination trades a small possible gain for an allergy and nutrition risk. A clear, immediate reaction to a food is a separate matter that does warrant assessment. For the eczema itself, treating the skin does far more.
Daily moisturizer from birth was hoped to head off eczema before it starts. In the large trials that tested it in babies at high family risk, it did not: eczema was just as common in the infants moisturized daily as in those who were not, 31% against 28%, and food allergy, asthma and hay fever were no less common either. Moisturizers work as treatment for eczema that has already appeared; they do not prevent it.
Probiotic supplements do not clear eczema you already have. Pooling 39 trials, they made little or no difference to how itchy or bad the eczema was, or to quality of life. Taking probiotics in pregnancy or infancy to try to prevent eczema is a separate and more contested question; for treating eczema you already have, the trials have settled it.
How It Works
Eczema runs on two faults that make each other worse: a leaky skin barrier and a type-2 immune overreaction. The outermost skin layer, the stratum corneum, normally keeps water in and allergens and microbes out. Loss-of-function mutations in the filaggrin gene are the main inherited risk, weakening that barrier, though many people with eczema have normal filaggrin, so it raises risk without accounting for every case. Once the barrier leaks, type-2 inflammatory signals, chiefly interleukin-4 and interleukin-13, suppress other barrier genes, change the skin's lipids, and drive the itch. The damaged barrier also lets Staphylococcus bacteria overgrow, which feeds the inflammation further.
This is why the treatments that work target one or both faults. Emollients rebuild the barrier from the outside. Steroids and calcineurin inhibitors calm the local inflammation. Dupilumab blocks interleukin-4 and interleukin-13 directly, and the JAK inhibitors block the signaling those cytokines use. And it is why treating the skin, not searching for a food to remove, is the foundation: the problem is in the barrier and the immune response, and that is where the effective treatments act.
Go Deeper
- Vitamin D: the low-risk supplement that modestly improved eczema severity, and where it sits as an adjunct rather than a treatment.
- Whole foods: eating for skin and general health without the risks of cutting whole foods out on the strength of an eczema hunch.
- The oral and skin microbiome: how the microbes living on us shape inflammation, the backdrop to why probiotics have been tried and why Staphylococcus matters in eczema.
- Asthma: the airway end of the atopic march that so often travels with eczema.
- Hay fever and allergic rhinitis: the other common companion of eczema, and how it is managed on its own terms.
The Chinese Medicine View
Chinese medicine never read eczema as one thing. It is an established classical dermatology domain, named 濕疹 shī zhěn, and the tradition differentiates by how the skin behaves. This is an interpretive lens on constitution and the pattern of the skin, not a reading of the barrier or the filaggrin gene, and a qualified practitioner working from a traceable herbal supply is the way to use it, because diagnosis by pattern needs an in-person examination. Read it alongside the modern picture, and the two accounts describe many of the same features.
The acute flare, red, weeping and intensely itchy, that a dermatologist calls an exacerbation maps onto what Chinese medicine calls damp-heat: heat in the skin and damp in the ooze, worse in heat and humidity. The direction of treatment is to clear the heat and drain the damp.
The chronic end is different. Dry, thickened, leathery skin that itches worse at night, the lichenified eczema of years of scratching, is read as blood deficiency with dryness and wind: too little blood to moisten the skin, with wind driving the itch. The direction is to nourish blood, moisten dryness and settle the wind. Other patterns sit between these: wind-heat for a sudden widespread eruption, and spleen deficiency with damp for the pale, puffy, oozing skin often seen in children.
Held as two lenses, neither validates the other, and strength is not endorsement. The trial evidence for Chinese herbal formulas in eczema is emerging and quality-limited: the pooled studies showed more people rated as recovered and fewer relapses, but the harder severity scores did not clearly move, and most trials were small and single-region. It is a promising signal, not settled evidence.
The main safety concern here is the product, not the herb. Some marketed herbal eczema creams, particularly unlabeled or imported ones, have been found adulterated with undisclosed potent steroids, so the safety of an unverified product is not the safety of the studied formula. If you want to explore herbal treatment, do it through a qualified practitioner using a regulated, traceable supply, not a cream bought online.
Cautions
Extra restraintEverything to be aware of is here, in one place. This practice suits most healthy people; a few situations call for real care.
The feared cancer link with calcineurin creams did not appear across 3.4 million patients
As part of the 2022 US allergy-immunology atopic dermatitis guidelines, reviewers pooled 110 studies (52 RCTs, 69 non-randomized) including roughly 3.4 million patients followed for a mean of 11 months. Using Bayesian models against patient-set thresholds, the absolute cancer risk was not raised by topical calcineurin inhibitor exposure. The original 2006 regulatory warning was precautionary, extrapolated from oral immunosuppression in transplant patients and animal work at far higher systemic exposures than a skin cream produces.Devasenapathy et al., Cancer risk with topical calcineurin inhibitors for atopic dermatitis: a systematic review and meta-analysis
Eczema herpeticum: fast-spreading, painful, punched-out sores that need same-day antiviral care
A subset of people with atopic dermatitis develop eczema herpeticum, a widespread herpes simplex virus infection over eczematous skin that can lead to serious, occasionally fatal complications. It is predisposed by the type-2 immune skewing, impaired antimicrobial peptides (reduced human beta-defensins and LL-37), filaggrin barrier defects, and Staphylococcus aureus overgrowth that mark more severe eczema. Clinically it is rapidly worsening, painful, with monomorphic dome-shaped vesicles and punched-out erosions, frequently with fever and malaise, and it warrants urgent systemic antiviral therapy (aciclovir). Dupilumab treatment reduces the risk. This is a safety claim rather than a treatment effect, so it carries no direction.Traidl et al., Eczema herpeticum in atopic dermatitis
Getting the steroid strength right
Topical steroids are matched to the site: mild on the face, eyelids and skin folds, stronger on thick or lichenified skin. Prolonged use of potent steroids on delicate areas can thin the skin, and prolonged potent use, most often on the face or genitals, can lead to topical steroid withdrawal, an uncommon reaction a regulator formally flagged in 2021. That is a reason to step down with guidance. Correct short courses on active eczema are not what causes it. If you find yourself using a strong steroid continuously, that is the point to review the plan with a clinician.
Unlabeled creams and hidden steroids
Some "natural" or imported eczema creams sold online have been found to contain undisclosed potent steroids. That means an unlabeled product can be far stronger than it appears, applied in the wrong place and for too long without anyone knowing. Buy from regulated suppliers and qualified practitioners rather than unverified online sellers, and if a cream is working suspiciously well without a label to explain why, have it and your skin reviewed.
The severe-disease drugs are specialist-monitored
Dupilumab and the oral JAK inhibitors are for moderate-to-severe eczema and are prescribed and monitored by a specialist. Dupilumab can cause conjunctivitis and injection-site reactions. The JAK inhibitors carry class boxed warnings covering serious infections, blood clots, cardiovascular events and malignancy, drawn largely from an older rheumatoid-arthritis population, and need baseline and periodic blood monitoring. The choice weighs speed against that safety profile with a dermatologist.
Eczema is miserable and often affects children, and none of this is meant to frighten you off treatment. It is manageable, most people control it well with moisturizing and the right cream used properly, and these notes are here to help you use the treatments confidently rather than to warn you away from them.
When to See Someone
Most eczema is managed with the moisturizers, creams and habits above and never needs more. These are the situations where a professional is the right next step, and the first three need care the same day. This is the When to See Someone list to come back to:
- Rapidly spreading, painful skin with clusters of uniform, punched-out sores or blisters, usually with fever and feeling unwell. This can be eczema herpeticum, a herpes infection of eczema-affected skin, and it is a medical emergency needing urgent antiviral treatment(seek urgent care)
- Widespread weeping, yellow crusting, spreading redness, pain or fever, which points to an infected flare that needs treating rather than more steroid alone(seek urgent care)
- Eczema turning red and inflamed over almost the whole body, especially with shivering or feeling unwell (erythroderma), which needs urgent assessment(seek urgent care)
- In a baby or young child, poor weight gain or faltering growth alongside severe or widespread eczema, which needs a proper assessment
- A severe flare that will not settle with your usual treatment, or eczema that is not improving at all despite using the creams correctly
- Eczema on or around the eyes with any change in vision, or eyelid skin that is not settling
- If you have been using an unlabeled or imported "natural" eczema cream, some of which have been found to contain undisclosed potent steroids, have the cream and your skin reviewed by a professional
- Eczema that started in adulthood and is spreading or behaving unusually, or a single patch that will not clear, which a clinician should check to confirm it is eczema and not something else
None of this is meant to alarm you. Eczema is common, it is manageable, and most people control it well with moisturizing and the right cream used properly. Knowing the few signs that need same-day care is simply part of managing it with confidence.
Common Questions
Is eczema caused by a food allergy?
Usually not. Eczema is a skin-barrier and immune condition, driven by a leaky barrier and an overreacting immune system, not by something in the diet. Food allergy travels with it, part of the same atopic tendency, but it rarely drives the eczema itself. That is why treating the skin works and why broad food-elimination diets do little: across the trials they gave at most a slight improvement, and cutting out a food a child was tolerating can bring on a new allergy to it later.
Are steroid creams safe to use on eczema?
Used correctly they are safe and they are the main treatment for a flare. In the trials about two in three people improved on a topical steroid against about one in three on the moisturizer base, with side effects no more common than in the base group. The skin thinning people fear comes from prolonged use of strong steroids on delicate skin, not from short courses matched to the site. The bigger problem in practice is the opposite: fear of the cream leads people to use too little, and their eczema quietly stays active.
What is the single most important thing for controlling eczema?
Moisturizing, applied generously and often, all over and every day. In the trials daily emollient use roughly halved flares, stretched the time to the next flare from about a month to about six months, and cut how much steroid cream people needed. The amount matters more than the brand, and keeping it up when the skin looks clear is what holds the next flare off.
How do I keep eczema from flaring once it clears?
Keep treating the spots that keep flaring, even after they look normal. Dabbing an anti-inflammatory cream on the usual trouble areas twice a week pushed the median time to the next flare from about two weeks to nearly five months in the trial that tested it. This proactive maintenance suits skin that repeatedly flares in the same places.
What are the options for severe eczema?
For eczema that covers much of the body and does not respond to creams, the specialist treatments are effective. Dupilumab, an injected biologic, cleared or nearly cleared the skin in about a third of people against under one in ten on placebo. The oral JAK inhibitors work faster still, easing itch within a couple of weeks, but need blood-test monitoring. Phototherapy, a course of narrowband UVB light at a clinic, sits between the creams and these drugs. All of these are prescribed and supervised by a dermatologist.
When should I get eczema seen the same day?
The one to know is eczema herpeticum: rapidly spreading, painful, punched-out sores or blisters, usually with fever and feeling unwell. It is a herpes infection of eczema skin and a medical emergency needing urgent antiviral treatment. Widespread weeping, yellow crusting and spreading redness with fever, which suggests an infected flare, and eczema turning red over almost the whole body with shivering, also need care the same day. These and the rest are gathered in the When to See Someone section above.
Explore Related
Other pages this one connects to, by the evidence they share, the outcomes they touch, and the ground they cover.
All 18 sources on this page independently checked and cross-referenced.
Thomas Dehli, Founder & Editor, Sacred Lotus
Sacred Lotus has published Chinese medicine reference material since 2001. Integrative pages are held to the same standard as the herb and formula library: cite the source, grade the claim at its real strength, and say where the research has not looked. This page is educational and it is not medical advice. Last reviewed and updated August 9, 2026.
Evidence strength
How confidently the research supports a claim. Strength describes the evidence, not our endorsement.